<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885740</url>
  </required_header>
  <id_info>
    <org_study_id>2009-A01197-50</org_study_id>
    <nct_id>NCT02885740</nct_id>
  </id_info>
  <brief_title>Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart</brief_title>
  <acronym>FACS</acronym>
  <official_title>Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the association of atrial fibrillation onset in
      normal heart and:

        -  Genetic determinants (genes of receptors, enzymes involved in synthesis and degradation,
           genes of bioavailability of coenzymes and nutritional precursors)

        -  Metabolic determinants of adenosine and methionine cycles

        -  Nutritional determinants.

      Secondary purposes are:

        -  Analysis of physiopathologic mechanisms of AF in normal hearts and adenosine metabolisms
           and its interaction with methionine metabolism, according to identified genetic
           determinants

        -  Analysis of blood markers of adenosine and methionine metabolites as phenotypic markers
           of detected polymorphisms

        -  Evaluate the role of adenosine receptors in AF onset
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most frequent arrhythmia and its causes are not well known.
      Experimental and clinical studies showed that activation of parasympathetic system can induce
      and maintain AF. Adenosine is a cardiovascular modulator with effects on vascular tonus and
      activation of nodal tissue through the activation of A1, A2A, A2B et A3 receptors.
      Intracellular production of adenosine is directly dependent (30%) on the hydrolysis of
      S-adenosylhomocysteine (SAH) by S-adenosylhomocysteine hydrolase in methionine cycle.
      Cellular production of adenosine depends on ratio SAH/S-adenosylmethionine (SAM) and
      modulates the expression of receptors. Other potential interactions between this 2
      metabolisms in AF are: 1) ratio SAM/SAH influences epigenetic mechanisms that can modify the
      expression of candidate genes involved in synaptic transmission and potassium canals, 2)
      ratio SAM/SAH influences also the cellular production of homocysteine with effects on
      cellular polarization, 3) adenosine and homocysteine are factors involved in thrombophilia
      and potentially associated to thromboembolic complications of AF.

      This study will evaluate the genetic (micro SNP-array) and adenosine and methionine metabolic
      determinants in the physiopathology of AF in normal hearts.

      Perspectives of this study are the prevention of AF in normal hearts through a nutritional
      and metabolic approach in subjects having a multigenic predisposition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of genetic polymorphisms related to adenosine and methionine metabolism</measure>
    <time_frame>day 0</time_frame>
    <description>Increase of frequency in patients having an AF in normal heart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of adenosine and methionine cycle nutritional and metabolic determinants</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of nutritional and methionine cycle metabolic determinants according to thromboembolic complications of AF in normal heart</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation in normal heart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having atrial fibrillation in normal heart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients having a junctional supraventricular tachycardia in normal heart</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quantification assay of adenosine and methionine cycle metabolites</intervention_name>
    <arm_group_label>Atrial fibrillation in normal heart</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Polymorphism analysis of genes related to adenosine metabolism and methionine cycle</intervention_name>
    <arm_group_label>Atrial fibrillation in normal heart</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quantitative and qualitative nutritional evaluation</intervention_name>
    <description>Questionnaire on consumption of 208 foods and drinks</description>
    <arm_group_label>Atrial fibrillation in normal heart</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Atrial fibrillation in normal heart</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Affiliation to French social security plan

        AF in normal heart:

        - Atrial fibrillation in normal heart

        Control:

        - Junctional supraventricular tachycardia in normal heart

        Normal heart: absence of macroscopic cardiomyopathy (echocardiography and normal ejection
        fraction)

        Exclusion Criteria:

          -  Considerable consumption of coffee (&gt; 50 mg/day, 15 cups/day)

          -  Actual administration of drugs interfering with adenosine metabolism: dipyridamole and
             methotrexate

          -  Actual administration interfering with methionine metabolism: folates, methotrexate
             and anticonvulsants

          -  Known renal insufficiency

          -  Known hypo- or hyperthyroidism

          -  Refusal or impossibility of informed consent

          -  Pregnant or breastfeeding women

          -  Person deprived of liberty

          -  Person under legal protection or not able to consent

          -  Person in emergency situation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne ALIOT, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département de Cardiologie, CHU Nancy, Hôpitaux de Brabois, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne ALIOT, Pr</last_name>
    <email>e.aliot@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Département de Cardiologie, CHU Nancy, Hôpitaux de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne ALIOT, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

